Cadence files intravenous paracetamol for US approval
This article was originally published in Scrip
Cadence Pharmaceuticals has submitted a marketing application for an intravenous formulation of acetaminophen (paracetamol) in the US, where it will be marketed as Acetavance.
You may also be interested in...
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.